and may guide intensification of treatment of COVID-19-associated uncontrolled inflammation (183, 261, 262, 265, 267269)
By purchasing, the buyer represents and warrants that this product will be used solely for legitimate in-vitro research purposes in an appropriate laboratory setting.
Not intended for human or animal use
Therefore, larger, controlled studies incorporating objective imaging and functional outcomes are needed to clarify efficacy, durability, and comparative benefits
References: [1] pmc/articles/PMC6271067/ [2] science/article/abs/pii/S00219673 12014550 [3] United States TB500 & BPC-157 Blend Nasal Spray Specifications: BPC-157: Sequence : Gly- Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ma Asp-Asp Ala Gly Leu Val Molecular Formula: C62H98N16O22 Molecular Weight: 1419.556 Explore our complete range of BPC-157 products here
A recipients individual risks for severe disease and current COVID-19 conditions in the community should be taken into account when deciding whether to delay vaccination up to 3 months after infection